Timo Soeterik

36 CHAPTER 2 TABLE 3. Correlation between clinical stage, PRIAS criteria and time to tumour progression Kaplan-Meier Cox regression Univariate Cox-regression Multivariate Median AS time a (years) Hazard ratio 95% CI p Hazard ratio 95% CI p Age years 0.99 0.98–1.01 0.397 0.99 0.97–1.00 0.088 PSA >10 ≤10 5.4 6.0 1.12 0.88–1.41 0.361 - - - PSAD ≥0.2 <0.2 3.1 7.3 2.03 1.67–2.45 <0.001 2.01 1.67–2.44 <0.001 Gleason ≥7 ≤6 5.3 6.0 1.35 0.89–2.05 0.165 - - - Positive cores >2 ≤2 3.6 5.6 1.62 1.28–2.06 <0.001 1.57 1.24–2.00 <0.001 PRIAS b No Yes 3.7 6.4 c 1.74 1.44–2.11 <0.001 - - - No. of criteria ≥2 ≤1 3.0 6.8 1.78 1.42–2.22 <0.001 - - - T3 or higher ≥cT3 ≤cT2 d 3.6 5.9 1.28 0.48–3.44 0.621 - - - a Median follow-up time on active surveillance (time to event). b PRIAS: complying with all PRIAS criteria (≤cT2, PSA ≤10, PSA density <0.2, Gleason score ≤6 and positive cores ≤2). c Mean value; median value could not be calculated since no more than 50% of patients discontinued. TABLE 4. Risk of unfavourable outcomes after delayed prostatectomy Non-nerve sparing a OR (95% CI) P Positive margin OR (95%CI) P Unfavourable histology b OR (95% CI) P Biochemical progression OR (95% CI) P Non- PRIAS vs. PRIAS 1.49 (0.73 – 3.03) 0.269 2.15 (1.11 – 4.17) 0.023 3.20 (1.61 – 6.35) 0.001 1.98 (0.75 – 5.23) 0.168 PSAD ≥0.2 1.23 (0.59 – 2.59) 0.586 1.97 (1.03 – 3.79) 0.042 3.61 (1.85 – 7.05) <0.001 3.26 (1.23 – 8.64) 0.018 Positive cores >2 1.59 (0.61 – 4.17) 0.342 2.96 (1.26 – 6.94) 0.013 1.89 (0.83 – 4.34) 0.132 3.69 (1.32 – 10.35) 0.013 a Non-nerve sparing (including partial, unilateral and non-nerve sparing). b Unfavourable pathology defined as presence of pT ≥T3 and/or pathological Gleason score ≥8.